Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.-MedSci.cn

Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.

Merle, P; Edeline, J; Bouattour, M; Cheng, AL; Chan, SL; Yau, T; Garrido, M; Knox, JJ; Daniele, B; Zhu, AX; Breder, VV; Lim, HY; Ogasawara, S; Siegel, AB; Rahman, A; Wei, ZW; Finn, RS

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3):

科室
- - 订阅+
  - 更多科室
工具
服务